FRANKFURT (Reuters) - Bayer (ETR:BAYGN)'s finance chief said on Wednesday that the drugs and pesticides maker would remain very selective when considering any further settlements of U.S. litigation cases in which plaintiffs blame their cancer on Bayer's Roundup weedkiller.
"We have no appetite to write humongous checks," said CFO Wolfgang Nickl in a media call after the release of third-quarter results. He added that Bayer has sound legal and scientific arguments to pursue its cases and appeals in court.
Last week, a California jury found Bayer liable in a case brought by a man who claimed his cancer was due to exposure to the company's glyphosate-based Roundup, the third consecutive defeat for Bayer. Before that, Bayer had won nine cases in a row.
BAYGN: is this perennial leader facing new challenges?
With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is BAYGN one of them?
Unlock ProPicks AI to find out